This combination is a well‐established treatment for HER2‐positive breast cancers, particularly in metastatic settings, as demonstrated by the CLEOPATRA trial, which showed improved progression‐free survival (PFS) and overall survival (OS) in HER2‐positive metastatic breast cancer. Here, ERBB2 is linked to breast carcinoma.